Navigation Links
Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients
Date:11/1/2008

com" target="_new">http://www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's clinical development plans and the potential for boceprevir. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part II, Item 1A, "Risk Factors" in the company's third quarter 2008 10-Q.

Endnotes

1. Kwo P, Lawitz E, McCone J, et al. Boceprevir Plus Peginterferon alfa-2b/Ribavirin for Treatment of Genotype 1 Chronic Hepatitis C in Previously Untreated Patients: Interim Results from the HCV SPRINT-1 Study. 59th American Association for the Study of Liver Diseases (AASLD) Annual Meeting; Oct. 31-Nov. 2, 2008, San Francisco, CA, USA; Poster No. LB16.

2. SVR, the protocol specified primary efficacy endpoint, is defined as achievement of undetectable HCV-RNA at 24 weeks after the end of treatment. Per protocol, if a patient does not have a 24-week post-treatment assessment, the patient's 12-week post-treatment assessment will be utilized.

3. SVR 12 is defined as undetectable HCV-RNA in plasma at 12 weeks after the end of treatment. The protocol specified primary effic
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
2. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
3. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
4. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
5. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
6. Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
9. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
10. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 2014 Though therapies are in their nascent ... show an annual increase of 16.2% over the 2010-2020 ... billion, according to Kalorama Information,s report, Stem Cell ... therapeutics that have gained or are expected to gain ... developers tackle ever more complicated conditions, stem cell therapies ...
(Date:10/30/2014)... -- Misonix, Inc. (NASDAQ: MSON ), an international ... innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery and ... financial results for the first quarter fiscal year 2015 ... a conference call that same day, Thursday, November 6, ... Interested parties can access the conference ...
(Date:10/30/2014)... -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX ), ... serving the pharmaceutical, biotechnology, and medical device industries, with ... the United States , today announced the ... Tel Aviv area of Israel.  ... of integrated R&D services to local customers. It will ...
Breaking Medicine Technology:Report: Stem Cell Technologies Market Growing 2Misonix, Inc. To Report First Quarter Fiscal Year 2015 Financial Results On Thursday, November 6, 2014 2WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax 2
... LAKE, N.J., April 27, 2011 Par Pharmaceutical Companies, Inc. ... settlement in principle to resolve claims brought by the pharmacy ... United States, Texas, and Florida under state and federal law, ... Alaska, South Carolina, and Kentucky under state law for $154 ...
... Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) will be ... on Wednesday, May 4, 2011 at 12:15 p.m. ET ... president, finance and chief financial officer at Amylin Pharmaceuticals, will ... webcast live through the "Investors" section of Amylin,s corporate website ...
Cached Medicine Technology:Par Pharmaceutical Companies Announces Settlement in Principle Regarding Certain Drug Pricing Lawsuits 2
(Date:10/31/2014)... NY (PRWEB) October 31, 2014 ... the most remarkable gifts of life — building a ... matching extraordinary surrogate mothers and donors with hopeful intended ... in unforeseen circumstances. , It’s a collective aptitude of ... agencies, surrogacy lawyers, and fertility clinics that help provide ...
(Date:10/31/2014)... FL (PRWEB) October 31, 2014 Triple ... volunteered his hair restoration services to transform the appearance ... of the American Academy of Facial Plastic and Reconstruction ... his time to restore the facial hair Jones lost ... , The pro-bono hair restoration procedure, valued around ...
(Date:10/31/2014)... October 31, 2014 BCC Research ( http://www.bccresearch.com ... AIR QUALITY MARKET , the U.S. indoor air quality (IAQ) ... with a compound annual growth rate (CAGR) of 7% over ... to grow at a CAGR of 7.4%. , Since ... toxic mold, the outbreak of infectious diseases such as bird ...
(Date:10/31/2014)... Radiology and EMR Integration , ... between diagnostic imaging centers but Connectivity is Opportunity,” ... “Differentiation is critical in all businesses today ... consider the intense competition and the downward pressure ... stand-out from the competition by fully integrating with ...
(Date:10/31/2014)... Adults 65 and older who are ... during the current open enrollment period can turn ... guidance, the company announced today. , The library ... correct Medicare Advantage plan, understanding the differences in ... “With just one month remaining of open enrollment, ...
Breaking Medicine News(10 mins):Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 3Health News:Miami Hair Restoration Specialist Transforms Wounded Soldier 2Health News:Global Market for U.S. Indoor Air Quality (IAQ) to Reach $11.4 Billion by 2019; Equipment Market Segment Surging at 7.4% CAGR 2Health News:Global Market for U.S. Indoor Air Quality (IAQ) to Reach $11.4 Billion by 2019; Equipment Market Segment Surging at 7.4% CAGR 3Health News:Diagnostic Imaging of Salem Expects Growth Partnering with DigitalOne 2
... adults at risk of developing sickle cell disease related ... that measures the levels of the enzyme lactate dehydrogenase ... by sickle shaped red blood cells with compromised oxygen ... blood cells are some rich sources of the enzyme, ...
... abortions, which may be a challenging to the women's right ... ,The law was essentially designed to challenge a ... that made it legal for women across the nation to ... of President George W. Bush's Republican Party, acknowledged as much ...
... put on high alert, as 600 new cases of hand-foot-mouth disease ... ,Deputy head of disaster relief George Chan Hong Nam ... three days, bringing this year's total to more than 1,500 cases. ... consequences can be serious," Chan was quoted as saying by the ...
... at the community-built Riverina Cancer Care Centre is looking forward ... which will bring about the much needed respite after the ... by the cancer support groups that people may avoid treatment ... Federal Member for Riverina, is hopeful of a positive outcome ...
... of Australian snakes can rapidly arrest bleeding during major trauma ... development of the next generation of therapeutic drugs for humans. ... amounts of a blood-clotting protein, referred to as factor X. ... been identified by Liam St Pierre, a researcher from Queensland ...
... might soon find themselves on the plane to the gulf, not ... of people in the Gulf. // The demand for rabbit meat ... the oasis in the desert, for what was a dry gulf ... options of importing rabbit meat and this has led to several ...
Cached Medicine News:Health News:LDH Measurement Can Predict Outlook Of Patients With SCD 2Health News:Australian Snake Venom Can Arrest Bleeding During Surgery And Trauma 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: